- Home
- SNTI vs BRNS Comparison
SNTI vs BRNS Comparison
Compare SNTI & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNTI | BRNS |
|---|---|---|
| Founded | 2016 | 2016 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.6M | 55.9M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | SNTI | BRNS |
|---|---|---|
| Price | $1.23 | $0.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $9.00 | $4.00 |
| AVG Volume (30 Days) | ★ 4.1M | 103.6K |
| Earning Date | 11-13-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $150.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 1766.46 |
| 52 Week Low | $1.26 | $0.64 |
| 52 Week High | $5.96 | $2.92 |
Technical Indicators
Market Signals| Indicator | SNTI | BRNS |
|---|---|---|
| Relative Strength Index (RSI) | 33.44 | 36.70 |
| Support Level | $1.34 | $0.68 |
| Resistance Level | $2.88 | $0.78 |
| Average True Range (ATR) | 0.24 | 0.07 |
| MACD | -0.10 | 0.02 |
| Stochastic Oscillator | 0.62 | 19.60 |
Price Performance
Historical ComparisonAbout SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.